RecruitingNot Applicable

Impact of HPV Vaccination on Prevention of Cervical HPV Infection in Sikkim, India

India5,500 participantsStarted 2020-10-01

Plain-language summary

This project aims is to monitor the effectiveness of HPV vaccination in real-word conditions, at least 7 years after initiation of HPV vaccination in Sikkim. This study would give an opportunity to provide rapid feedback to the Indian public health authorities about the impact of the HPV vaccine.

Who can participate

Age range18 Years – 22 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women aged 18 to 22 years, resident of Sikkim and married. * Pregnancy will not be considered as exclusion criteria. * Sample collection should be avoided during active menstruation. Exclusion Criteria: * Women who do not provide written consent * Women who are not able to cooperate in collection of cervical cell sample or respond to questions due to any acute or severe mental and physical illnesses. * Women who had undergone hysterectomy. * Vaccinated in research project

What they're measuring

The reduction in the point prevalence of genotype-specific HPV infection in women within 7 years of initiation of HPV vaccination compared to that at baseline

Timeframe: 7 years

The difference in the point prevalence of chlamydia trachomatis infection in women within 7 years of initiation of HPV vaccination compared to that at baseline

Timeframe: 7 years

Trial details

NCT IDNCT04588402

SponsorInternational Agency for Research on Cancer

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-10-30

Contact for this trial

Partha Basu, MD, PhD

+33 472 738 167 basup@iarc.fr

View on ClinicalTrials.gov More Cervical Cancer trials